|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 212.42Cr 185.23Cr 174.9Cr 158.82Cr 297.56Cr 20TCr 298.81Cr 2.1TCr 808.46Cr 10TCr 797.94Cr 780.22Cr 33TCr | P/E 2026 * |
6.37x | P/E 2027 * | 35x |
|---|---|---|---|---|---|
| Enterprise Value | 184.02Cr 160.46Cr 151.52Cr 137.59Cr 257.78Cr 18TCr 258.86Cr 1.81TCr 700.38Cr 8.98TCr 691.27Cr 675.92Cr 29TCr | EV / Sales 2026 * |
1x | EV / Sales 2027 * | 1.01x |
| Free-Float |
94.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Sarepta Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Severino
CEO | Chief Executive Officer | 60 | 28/07/2026 |
Ryan Wong
DFI | Director of Finance/CFO | 47 | 16/07/2025 |
Ian Estepan
DFI | Director of Finance/CFO | 50 | 14/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 73 | 16/04/2015 |
| Director/Board Member | 87 | 01/06/2010 | |
Richard Barry
BRD | Director/Board Member | 67 | 02/06/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.71% | -1.66% | +15.38% | -83.12% | 212.42Cr | |
| +0.07% | +1.47% | -48.42% | -60.13% | 142.62Cr | |
| -1.27% | -2.21% | -25.04% | -7.09% | 34Cr | |
| +0.43% | +4.50% | -46.54% | - | 5.34Cr | |
| Average | -0.87% | +0.76% | -26.16% | -50.11% | 98.55Cr | |
| Weighted average by Cap. | -1.54% | -0.48% | -12.01% | -68.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 183.75Cr 160.23Cr 151.3Cr 137.39Cr 257.41Cr 18TCr 258.49Cr 1.81TCr 699.37Cr 8.96TCr 690.28Cr 674.95Cr 29TCr | 138.44Cr 120.72Cr 113.99Cr 103.51Cr 193.94Cr 13TCr 194.75Cr 1.37TCr 526.92Cr 6.75TCr 520.07Cr 508.52Cr 22TCr |
| Net income | 37Cr 32Cr 30Cr 27Cr 51Cr 3.51TCr 51Cr 360.65Cr 139.17Cr 1.78TCr 137.36Cr 134.31Cr 5.74TCr | 3.94Cr 3.44Cr 3.25Cr 2.95Cr 5.52Cr 378.2Cr 5.54Cr 39Cr 15Cr 192.28Cr 15Cr 14Cr 618.69Cr |
| Net Debt | -28Cr -25Cr -23Cr -21Cr -40Cr -2.72TCr -40Cr -280.07Cr -108.08Cr -1.39TCr -106.67Cr -104.3Cr -4.46TCr | -72Cr -63Cr -60Cr -54Cr -101.38Cr -6.94TCr -101.81Cr -713.79Cr -275.45Cr -3.53TCr -271.87Cr -265.83Cr -11TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
